Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT

PLoS ONE

Volumn 4, Issue 9, 2009, Pages

  Dubreuil, Patrice ^a,b,c,d   Letard, Sébastien ^a,b,c,d   Ciufolini, Marco ^d,e   Gros, Laurent ^d   Humbert, Martine ^d   Castéran, Nathalie ^d   Borge, Laurence ^a,b,c   Hajem, Bérengère ^d   Lermet, Anne ^d   Sippl, Wolfgang ^f   Voisset, Edwige ^a,b,c   Arock, Michel ^g   Auclair, Christian ^d,g   Leventhal, Phillip S ^d   Mansfield, Colin D ^d   Moussy, Alain ^d   Hermine, Olivier ^d,h  

^a AIX MARSEILLE UNIVERSITY   (France)

^b INSTITUT PAOLI CALMETTES   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d AB Science   (France)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^g CNRS   (France)

^h UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AB 1010; ABELSON KINASE; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 3; IMATINIB; MASITINIB; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE LYN; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; PROTEIN KINASE INHIBITOR; RECOMBINANT PROTEIN; THIAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CANCER CELL CULTURE; CARDIOTOXICITY; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEGRANULATION; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME INHIBITION; FEMALE; GENE MUTATION; GENOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MAST CELL; MASTOCYTOMA; MOLECULAR MODEL; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; SUBCUTANEOUS TISSUE TUMOR; TUMOR VOLUME; WILD TYPE; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG SCREENING; IC 50; METABOLISM; MUTATION; NUDE MOUSE;

ANIMALIA; MURINAE; MUS;

ANIMALS; BONE MARROW CELLS; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; MICE; MICE, NUDE; MODELS, MOLECULAR; MUTATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-KIT; RECOMBINANT PROTEINS; THIAZOLES;

EID: 70349658639     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0007258     Document Type: Article

References (37)

1. Roskoski R Jr (2005) Signaling by Kit protein-tyrosine kinase - the stem cell factor receptor. Biochem Biophys Res Commun 337: 1-13.
2. Broudy VC (1997) Stem cell factor and hematopoiesis. Blood 90: 1345-64.
3. Reber L, Da Silva CA, Frossard N (2006) Stem cell factor and its receptor c-Kit as targets for inflammatory diseases. Eur J Pharmacol 533: 327-40.
4. Tests U (2008) Kit mutations in cancer and their treatment with protein kinase inhibitors. Drugs Fut 33: 161-174.
5. Lennarttson J, Jelacic T, Linnekin D, Shivakrupa R (2005) Normal and Oncogenic Forms of the Receptor Tyrosine Kinase Kit. Stem Cells 23: 16-43.
6. Orfao A, Garcia-Montero AC, Sanchez L, Escribano L (2007) Recent advances in the understanding of mastocytosis: the role of KIT mutations. Br J Haematol 138: 12-30.
7. Arora A, Scholar EM (2005) Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 315: 971-9.
8. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, et al. (1995) Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc Natl Acad Sci USA 92: 2558-62.
9. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, et al. (1996) Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 56: 100-4.
10. Dewar AL, Cambareri AC, Zannettino AC, Miller BL, Doherty KV, et al. (2005) Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood 105: 3127-32.
11. Atwell S, Adams JM, Badger J, Buchanan MD, Feil IK, et al. (2004) A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase. J Biol Chem 279: 55827-32.
12. Rubin BP, Duensing A (2006) Mechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumours. Lab Invest 86: 981-6.
13. Ma Y, Zeng S, Metcalfe DD, Akin C, Dimitrijevic S, et al. (2002) The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 99: 1741-4.
14. Ueda S, Ikeda H, Mizuki M, Ishiko J, Matsumura I, et al. (2002) Constitutive activation of c-kit by the juxtamembrane but not the catalytic domain mutations is inhibited selectively by tyrosine kinase inhibitors STI571 and AG1296. Int J Hematol 76: 427-35.
15. Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, et al. (2006) Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12: 908-16.
16. Fernandez A, Sanguino A, Peng Z, Ozturk E, Chen J, et al. (2007) An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. J Clin Invest 117: 4044-54.
17. Kitayama H, Kanakura Y, Furitsu T, Tsujimura T, Oritani K, et al. (1995) Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumourigenicity of factor-dependent hematopoietic cell lines. Blood 85: 790-8.
18. Meininger CJ, Yano H, Rottapel R, Bernstein A, Zsebo KM, et al. (1992) The c-kit receptor ligand functions as a mast cell chemoattractant. Blood 79: 958-63.
19. Casteran N, De Sepulveda P, Beslu N, Aoubala M, Letard S, et al. (2003) Signal transduction by several KIT juxtamembrane domain mutations. Oncogene 22: 4710-22.
20. Tsujimura T, Morimoto M, Hashimoto K, Moriyama Y, Kitayama H, et al. (1996) Constitutive activation of c-kit in FMA3 murine mastocytoma cells caused by deletion of seven amino acids at the juxtamembrane domain. Blood 87: 273-83.
21. Small D (2006) FLT3 mutations: biology and treatment. Hematology Am Soc Hematol Educ Program. pp 178-84.
22. Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, et al. (2002) Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 62: 4236-43.
23. Mol CD, Dougan DR, Schneider TR, Skene RJ, Kraus ML, et al. (2004) Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem 279: 31655-63.
24. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, et al. (2004) BAY 43-9006 exhibits broad spectrum oral antitumour activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumour progression and angiogenesis. Cancer Res 64: 7099-109.
25. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, et al. (2003) In vivo antitumour activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9: 327-37.
26. Shchemelinin I, Sefc L, Necas E (2006) Protein kinase inhibitors. Folia Biol (Praha) 52: 137-48.
27. Imatinib new drug application #21-335 Gleevec Pharmacology Review http://www.fda.gov/cder/foi/nda/2001/21-335_Gleevec_pharmr_P1.pdf.
28. Zermati Y, De Sepulveda P, Feger F, Letard S, Kersual J, et al. (2003) Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene 22: 660-4.
29. Frost MJ, Ferrao PT, Hughes TP, Ashman LK (2002) Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther 1: 1115-24.
30. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, et al. (2003) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348: 1201-14.
31. Hahn KA, Oglivie G, Rusk T, Devauchelle P, Leblanc A, et al. (2008) Masitinib is Safe and Effective for the Treatment of Canine Mast Cell Tumors. J Vet Intern Med 22: 1301-1309.
32. Gabillot-Carre M, Lepelletier Y, Humbert M, de Sepuvelda P, Hamouda NB, et al. (2006) Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells. Blood 108: 1065-72.
33. Royer B, Varadaradjalou S, Saas P, Gabiot AC, Kantelip B, et al. (2001) Autocrine regulation of cord blood-derived human mast cell activation by IL-10. J Allergy Clin Immunol 108: 80-6.
34. Razin E, Mencia-Huerta JM, Stevens RL, Lewis RA, Liu FT, et al. (1983) IgE mediated release of leukotriene C4, chondroitin sulfate E proteoglycan, beta-hexosaminidase, and histamine from cultured bone marrow-derived mouse mast cells. J Exp Med 157: 189-201.
35. Zou YR, Kottmann AH, Kuroda M, Taniuchi I, Littman DR (1998) Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 393: 595-9.
36. Wang R, Lu Y, Wang S (2003) Comparative evaluation of 11 scoring functions for molecular docking. J Med Chem 46: 2287-303.
37. Circulaire ministérielle du 16 avril 1996 relative aux expérimentations confinées d'organismes génétiquement modifiés à des fins de recherche, développement ou d'enseignement. Journal Officiel du 2 juin 1996, pp.8167.